Healthcare to advance regenerative cartilage therapy to the clinic
Cambridge, UK, 1 st April 2019:
The Mogrify Platform (Rackham et al., Nature Genetics, 2016) has been used by
Osteoarthritis is a progressive disease of synovial joints resulting in the breakdown of articular cartilage and bone and is the most common joint disorder, affecting more than 30 million adults in the United States* alone. Current treatments only focus on addressing the symptoms, for instance, pain or inflammation, and in some cases result in total joint replacement.
Following on from a proof-of-concept study,
Dr Wael Kafienah, PhD, Director,
Pierre-Louis Joffrin, Corporate Development Executive, Mogrify, said: “Having started from various cell types, the produced chondrocytes are displaying all of the markers necessary for use as both autologous and allogeneic therapies which would represent a huge advancement in the standard of care of osteoarthritis. We are speaking with a number of commercial partners and clinical development specialists, and our focus is on bringing a new therapy to market to improve the lives of osteoarthritis
*Centers for Disease Control and Prevention
Rackham OJL et al. A predictive computational framework for direct reprogramming between human cell types. Nature Genetics. 2016 Mar;48(3):331-5.
For further information please contact:
Email: [email protected]
Tel: +44 (0)7811 996 942
E-mail: [email protected]
Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.
The platform takes a systematic big-data approach to identify, from next-generation sequencing and gene-regulatory networks, the transcription factors (in vitro) or small molecules (in vivo), needed
Mogrify is applying its patented technology to generate IP and cell types that will power the development and manufacture of new cell therapies across every therapeutic area. Uniquely positioned to address a cell therapy market estimated to be $35 billion USD by 2023, Mogrify is commercializing its technology via IP licensing, product development, and drug development. Based in Cambridge, UK, the Company has raised $3.7 million USD seed funding from Ahren Innovation Capital, 24Haymarket and Dr Darrin M Disley, OBE.
Follow Mogrify on Twitter @Mogrify_UK and LinkedIn @Mogrify
The company’s unique combination of skills has allowed us to find ways to precisely control the cellular fate of chondrocytes. We are using this knowledge to pioneer a novel first-in-class cartilage regenerative medicine. This new data-driven approach to the field of regenerative medicine allows us to find optimal treatment strategies without the need for costly trial and error optimization.
About SBRI Healthcare
SBRI Healthcare is an NHS England initiative, led by the Academic Health Science Network (AHSN), who aim to promote UK economic growth whilst addressing unmet health needs and enhancing the take up of known best practice.